TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration In Vitro TDI-011536 (3 µM; 24 h) reduces Yap phosphorylation and (3 µM; 5 days) induces proliferation of Müller glia in human retinal organoids. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: human retinal organoids Concentration: 3 µM Incubation Time: 24 h, 5 days Result: Supressed Yap phosphorylation and promoted Müller glia proliferation. In Vivo TDI-011536 (200 mg/kg; i.p.; once) provides over 4 h of Lats inhibition in the liver, heart, and skin and reduces the amount of pYap for at least 4 h after injection in all three organs . TDI-011536 (100 mg/kg; i.p.; once daily for 2 or 3 days) shows proliferative effect on cardiomyocytes . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Living mice (immunoblot analysis of the heart, liver, and skin immediately after injection) . Dosage: 200 mg/kg Administration: Intraperitoneal injections; once. Result: Reduced the amount of pYap for at least 4 h after injection in all three organs and the levels returned to control values within a day. Animal Model: Male 8-week-old mice (cryolesion model) . Dosage: 100 mg/kg Administration: Intraperitoneal injections; once daily for 2 or 3 days. Result: Promoted cardiomyocytes proliferation. Form:Solid IC50& Target:Lats kinase